Shanghai Tonglian Pharmaceutical

Shanghai Tonglian Pharmaceutical is a large-scale, integrated pharmaceutical group headquartered in Shanghai, China, specializing in the research, development, and high-volume manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company is a global leader in the production of erythromycin and its derivatives, utilizing advanced large-scale fermentation technologies. Its product portfolio spans multiple therapeutic areas, including anti-infectives, cardiovascular health, and metabolic disorders, with a significant presence in the insulin biosimilar market. Tonglian operates extensive manufacturing facilities, notably in Inner Mongolia, which support its vertically integrated business model from chemical synthesis to commercial distribution. The company serves both domestic and international markets, maintaining rigorous GMP compliance across its production bases.